Equity Profile

HAE

Haemonetics Corporation

Health CareHealth Care Supplies$3.5B

Aug6Thu

Pre-Earnings Brief

UpcomingQ1-2027Pre-Market9:00 AM EDT

Company Snapshot

Haemonetics Corporation (HAE) operates in the health care sector, focusing on medical supplies that aid in blood management and transfusion. The company's products are essential for hospitals and blood banks, making it a key player in the health care supplies industry.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its business and capture market share.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

HAE Q1-2027 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-4.77%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In the last quarter (Q4-2026), Haemonetics reported an EPS of $1.29, slightly beating expectations. The stock reacted positively, gaining 3.23% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance and positive EPS surprises in previous quarters. However, there is uncertainty due to the lack of specific guidance.

Bull Case

If Haemonetics continues its trend of beating EPS estimates, it could see a strong positive reaction from the market, especially if revenue growth is also robust.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2027?

EPS is a key indicator of profitability and will heavily influence investor sentiment and stock price.

How is revenue growth trending compared to previous quarters?

Understanding revenue growth is crucial for assessing the company's expansion and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Haemonetics' potential for revenue growth based on recent trends in blood management.

Supporting Evidence

The company has consistently beaten EPS estimates in the last few quarters, suggesting strong operational performance.

Options pricing indicates a lower expected move compared to historical averages, which may not reflect the company's growth potential.

Key Risk

If revenue growth exceeds expectations, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market will closely watch EPS and revenue growth to gauge the company's performance and future outlook.

Bull Confirmed If

An EPS of $1.35 or higher would confirm the bull case and indicate strong profitability.

Bear Confirmed If

An EPS below $1.00 would confirm the bear case, signaling potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±8.64%

Historical Avg

±12.8%

Pricing cheap

The options market is pricing in an 8.64% move, suggesting that traders expect some volatility around the earnings announcement.

Options are pricing ±8.6% while HAE has averaged ±12.8% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

47.6%

Calls (9K)P/C Ratio: 0.03Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Haemonetics beats expectations, history suggests the stock could rise by around 6.52%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may see a muted reaction.

Miss

A miss could lead to a decline of around 18.71%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in blood management technology.
2Insights into market demand for blood management solutions.
3Management's outlook on future revenue growth and market expansion.
4Details on cost management strategies and their impact on gross margins.
5Any commentary on competitive pressures in the health care supplies sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of a company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its business and capture market share.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

HAE Q1-2027 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-4.77%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In the last quarter (Q4-2026), Haemonetics reported an EPS of $1.29, slightly beating expectations. The stock reacted positively, gaining 3.23% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Haemonetics continues its trend of beating EPS estimates, it could see a strong positive reaction from the market, especially if revenue growth is also robust.

Bear Case

On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2027?

EPS is a key indicator of profitability and will heavily influence investor sentiment and stock price.

How is revenue growth trending compared to previous quarters?

Understanding revenue growth is crucial for assessing the company's expansion and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Haemonetics' potential for revenue growth based on recent trends in blood management.

Supporting Evidence

The company has consistently beaten EPS estimates in the last few quarters, suggesting strong operational performance.

Options pricing indicates a lower expected move compared to historical averages, which may not reflect the company's growth potential.

Key Risk

If revenue growth exceeds expectations, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market will closely watch EPS and revenue growth to gauge the company's performance and future outlook.

Bull Confirmed If

An EPS of $1.35 or higher would confirm the bull case and indicate strong profitability.

Bear Confirmed If

An EPS below $1.00 would confirm the bear case, signaling potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±8.64%

Historical Avg

±12.8%

Pricing cheap

The options market is pricing in an 8.64% move, suggesting that traders expect some volatility around the earnings announcement.

Options are pricing ±8.6% while HAE has averaged ±12.8% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

47.6%

Calls (9K)P/C Ratio: 0.03Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Haemonetics beats expectations, history suggests the stock could rise by around 6.52%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but cautious commentary is provided, the stock may see a muted reaction.

Miss

A miss could lead to a decline of around 18.71%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in blood management technology.
2Insights into market demand for blood management solutions.
3Management's outlook on future revenue growth and market expansion.
4Details on cost management strategies and their impact on gross margins.
5Any commentary on competitive pressures in the health care supplies sector.